Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study.
Antineoplastic Agents
/ chemical synthesis
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Glycoside Hydrolase Inhibitors
/ chemical synthesis
Humans
Hypoglycemic Agents
/ chemical synthesis
Kinetics
MCF-7 Cells
Molecular Docking Simulation
Molecular Structure
Quinazolinones
/ chemical synthesis
Structure-Activity Relationship
Triazoles
/ chemical synthesis
alpha-Glucosidases
/ metabolism
1,2,3-Triazole
Anti-diabetic activity
Competitive inhibition
Molecular docking
Quinazolinone
α-Glucosidase
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
12
08
2018
revised:
04
10
2018
accepted:
10
10
2018
pubmed:
27
10
2018
medline:
4
12
2019
entrez:
27
10
2018
Statut:
ppublish
Résumé
A novel series of quinazolinone-1,2,3-triazole hybrids 10a-p were designed, synthesized, and evaluated for their in vitro α-glucosidase inhibitory activity leading to efficient anti-diabetic agents. All synthesized compounds exhibited good inhibitory activity against yeast α-glucosidase (IC
Identifiants
pubmed: 30366316
pii: S0045-2068(18)30869-1
doi: 10.1016/j.bioorg.2018.10.023
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Glycoside Hydrolase Inhibitors
0
Hypoglycemic Agents
0
Quinazolinones
0
Triazoles
0
alpha-Glucosidases
EC 3.2.1.20
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-169Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.